OLMA250117P22500
- 0.00
- 0.000.00%
Olema Pharmaceuticals Newsroom
(SEC Amendment) Olema Pharmaceuticals(OLMA.US) Director Buys US$4.73 Million in Common Stock
$Olema Pharmaceuticals(OLMA.US)$ Director Graham G. Walmsley purchased 700.76K shares of common stock on Dec 13, 2024 at an average price of $6.75 for a total value of $4.73 million, and sold 700.76
Top 3 Health Care Stocks That May Explode In Q4
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Announces Target Price $30
J.P. Morgan Keeps Their Buy Rating on Olema Pharmaceuticals (OLMA)
Olema Pharmaceuticals Director Graham Walmsley Sells $4.73m in Stock
Express News | Olema Pharmaceuticals Inc : JP Morgan Raises Target Price to $30 From $29
Olema Pharmaceuticals Down Over 19%, on Pace for Largest Percent Decrease Since August 2022 -- Data Talk
Express News | Bain Capital Life Sciences Opportunities IV, L.p. Reports 9.99% Passive Stake in Olema Pharmaceuticals Inc as of Dec 4 - SEC Filing
Oppenheimer Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $30
Oppenheimer Remains a Buy on Olema Pharmaceuticals (OLMA)
TD Cowen Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating
TD Cowen Sticks to Their Buy Rating for Olema Pharmaceuticals (OLMA)
H.C. Wainwright Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $30
HC Wainwright & Co. Reiterates Buy on Olema Pharmaceuticals, Maintains $30 Price Target
Olema Pharmaceuticals Analyst Ratings
Olema Pharmaceuticals: Promising Clinical Data and Growth Potential Warrant a Buy Rating
Express News | Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination With Ribociclib at the San Antonio Breast Cancer Symposium
Olema Pharmaceuticals Announces FDA Clearance for OP-3136 IND Application, Phase 1 Clinical Trial Set to Begin in Early 2025
Olema Pharmaceuticals Cleared to Begin Testing Prospective Breast Cancer Candidate
Olema Pharmaceuticals Shares Are Trading Higher After the Company Announced the FDA Cleared the Investigational New Drug (IND) Application for OP-3136.